T-773

T-773 is a small molecule radioligand developed as a positron emission tomography (PET) imaging agent targeting phosphodiesterase 10A (PDE10A). It acts as a highly selective and high-affinity inhibitor of PDE10A, an enzyme predominantly expressed in striatal medium spiny neurons. By binding to PDE10A, T-773 enables visualization and quantification of this enzyme in the brain using PET imaging. The compound has demonstrated strong selectivity for PDE10A over other phosphodiesterases and accumulates selectively in the striatum during preclinical studies. Its primary use is as a diagnostic radiopharmaceutical for research into neurological disorders such as schizophrenia and Huntington's disease[3][4]. T-773 was initially developed by Takeda Pharmaceutical.